Endocrinol Metab.  2016 Sep;31(3):400-401. 10.3803/EnM.2016.31.3.400.

New Biological Markers of Bone Metabolism in Osteoporosis Treatment

• Cho SW

• KMID: 2352978
• DOI: http://doi.org/10.3803/EnM.2016.31.3.400

Abstract

No abstract available.

MeSH Terms

Biomarkers*
Metabolism*
Osteoporosis*
Biomarkers

Reference

1. Kim H, Ahn SH, Shin C, Lee SH, Kim BJ, Koh JM. The association of higher plasma macrophage migration inhibitory factor levels with lower bone mineral density and higher bone turnover rate in postmenopausal women. Endocrinol Metab (Seoul). 2016; 31:454–461.

2. Cho SW, Soki FN, Koh AJ, Eber MR, Entezami P, Park SI, et al. Osteal macrophages support physiologic skeletal remodeling and anabolic actions of parathyroid hormone in bone. Proc Natl Acad Sci U S A. 2014; 111:1545–1550.

3. Rousseau JC, Sornay-Rendu E, Bertholon C, Chapurlat R, Garnero P. Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J Clin Endocrinol Metab. 2014; 99:2533–2539.

4. Lee SH, Lee SY, Lee YS, Kim BJ, Lim KH, Cho EH, et al. Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans. J Clin Endocrinol Metab. 2012; 97:E1421–E1428.

5. Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res. 2012; 27:2592–2602.

6. Garnero P. New developments in biological markers of bone metabolism in osteoporosis. Bone. 2014; 66:46–55.